


Healthcare Industry News: HIV/AIDS
News Release - May 17, 2007
Health Canada approves REYATAZ(R) (atazanavir sulfate) 300 mg single capsule formulation in combination therapy for adults with HIV-1 infection
Source: Bristol-Myers Squibb
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
